AGIO Earnings & Financial Statements
Agios Pharmaceuticals, Inc.
$30.97
+$0.76(+2.52%)
51
Overall
60
Value
20
Tech
73
Quality
Market Cap
$1.85B
Volume
930.89K
52W Range
$19.45 - $44.09
Target Price
$44.78
AGIO earnings and financial statements: Agios Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AGIO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $54.03M | $36.50M | $26.82M | $14.24M | $500.0K |
| Cost of revenue | $6.34M | $4.17M | $2.88M | $1.70M | - |
| Operating income | -$472.13M | -$425.74M | -$391.49M | -$389.05M | -$378.42M |
| EBITDA | -$452.57M | $687.07M | -$368.09M | -$213.24M | -$369.18M |
| Net income | -$412.78M | $673.73M | -$352.09M | -$231.80M | $1.60B |
| EPS (diluted) | $-7.12 | $11.64 | $-6.33 | $-8.46 | $53.10 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.30B | $1.66B | $937.12M | $1.24B | $1.44B |
| Total liabilities | $104.11M | $122.24M | $126.10M | $137.90M | $145.76M |
| Shareholders’ equity | $1.19B | $1.54B | $811.02M | $1.10B | $1.29B |
| Cash and equivalents | $89.13M | $76.25M | $88.20M | $139.26M | $203.13M |
| Long-term debt | $21.82M | $40.21M | $56.99M | $72.00M | $85.94M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$372.98M | -$389.84M | -$296.06M | -$309.48M | -$407.32M |
| Capital expenditure | -$4.32M | -$1.65M | -$18.50M | -$4.88M | -$5.74M |
| Free cash flow | -$377.29M | -$391.53M | -$297.06M | -$314.36M | -$413.06M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AGIO | $30.97 | +2.5% | 930.89K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Agios Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW